FDA experts vote to pull AMAG's premature-birth med Makena from the market

thumbs down
AMAG Pharmaceuticals' Makena may not be long for the U.S. market after a no vote from an FDA advisory committee. (pixabay)

Already under pressure from its shareholders, AMAG faced a big decision from an FDA advisory committee on the future of its troubled premature-birth med Makena. Now, with the committee voting against it, Makena may not be long for the U.S. market. 

Tuesday, an advisory committee voted 9-7 to recommend Makena's marketing withdrawal after the drug faced questions about its efficacy over placebo. 

The seven committee members in dissent called for Makena to be put on accelerated approval and for a new confirmatory trial, arguing there were few treatments on the market for pregnant patients at risk of premature birth. AMAG said in a statement that it was disappointed with the recommendation. 

"We are disappointed with the nearly split vote on this key question and we are committed to working with the FDA to identify feasible ways to generate additional efficacy data on Makena while retaining current access to the therapy for at-risk pregnant women,” AMAG Chief Medical Officer Julie Krop said.

RELATED: FDA review of troubled drug could hobble AMAG in proxy fight with activist investor

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.